Heidelberg Pharma AG (LON:0QW5)
London
· Delayed Price · Currency is GBP · Price in EUR 2.640
0.00 (0.00%)
At close: Apr 14, 2025
Heidelberg Pharma AG Income Statement
Financials in millions EUR. Fiscal year is December - November.
Millions EUR. Fiscal year is Dec - Nov.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Nov '24 Nov 30, 2024 | Nov '23 Nov 30, 2023 | Nov '22 Nov 30, 2022 | Nov '21 Nov 30, 2021 | Nov '20 Nov 30, 2020 | 2015 - 2019 |
| Operating Revenue | 6.85 | 9.86 | 18.51 | 1.75 | 8.49 | Upgrade
|
| Other Revenue | - | - | - | 0.28 | 0.18 | Upgrade
|
| Revenue | 6.85 | 9.86 | 18.51 | 2.03 | 8.67 | Upgrade
|
| Revenue Growth (YoY) | -30.53% | -46.75% | 810.30% | -76.53% | 15.63% | Upgrade
|
| Cost of Revenue | 1.78 | 3.25 | 4.68 | 4.71 | 5.6 | Upgrade
|
| Gross Profit | 5.07 | 6.61 | 13.83 | -2.68 | 3.07 | Upgrade
|
| Selling, General & Admin | 8.46 | 6.22 | 5.99 | 4.48 | 3.97 | Upgrade
|
| Research & Development | 21.84 | 28.07 | 26.38 | 18.75 | 18.28 | Upgrade
|
| Other Operating Expenses | -3.4 | -0.14 | -0.24 | -0.07 | -0.11 | Upgrade
|
| Operating Expenses | 26.9 | 34.15 | 32.13 | 23.16 | 22.15 | Upgrade
|
| Operating Income | -21.83 | -27.55 | -18.29 | -25.84 | -19.09 | Upgrade
|
| Interest Expense | -0.14 | -0.76 | -0.84 | -0.49 | -0.01 | Upgrade
|
| Interest & Investment Income | 1.42 | 7.55 | 0.24 | - | - | Upgrade
|
| Earnings From Equity Investments | - | - | - | -0.01 | -0.07 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.18 | -0.46 | 0.96 | 0 | 0.02 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.12 | 0.21 | 0.06 | 0.09 | 0.14 | Upgrade
|
| EBT Excluding Unusual Items | -20.6 | -21.01 | -17.87 | -26.26 | -19.01 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0 | 0.03 | 0.02 | - | 0.01 | Upgrade
|
| Asset Writedown | - | - | - | - | -0 | Upgrade
|
| Other Unusual Items | 1.22 | 0.63 | 0.07 | 0.12 | 0.63 | Upgrade
|
| Pretax Income | -19.38 | -20.35 | -17.79 | -26.14 | -18.37 | Upgrade
|
| Income Tax Expense | - | - | 1.92 | - | - | Upgrade
|
| Net Income | -19.38 | -20.35 | -19.7 | -26.14 | -18.37 | Upgrade
|
| Net Income to Common | -19.38 | -20.35 | -19.7 | -26.14 | -18.37 | Upgrade
|
| Shares Outstanding (Basic) | 47 | 47 | 37 | 33 | 30 | Upgrade
|
| Shares Outstanding (Diluted) | 47 | 47 | 37 | 33 | 30 | Upgrade
|
| Shares Change (YoY) | 0.02% | 25.14% | 14.56% | 8.72% | 5.98% | Upgrade
|
| EPS (Basic) | -0.42 | -0.44 | -0.53 | -0.80 | -0.61 | Upgrade
|
| EPS (Diluted) | -0.42 | -0.44 | -0.53 | -0.80 | -0.61 | Upgrade
|
| Free Cash Flow | -30.04 | -34.61 | -9.45 | -27.85 | -19.26 | Upgrade
|
| Free Cash Flow Per Share | -0.65 | -0.74 | -0.25 | -0.86 | -0.64 | Upgrade
|
| Gross Margin | 74.00% | 67.01% | 74.72% | -131.69% | 35.39% | Upgrade
|
| Operating Margin | -318.71% | -279.41% | -98.81% | -1270.65% | -220.22% | Upgrade
|
| Profit Margin | -282.98% | -206.38% | -106.42% | -1285.20% | -211.95% | Upgrade
|
| Free Cash Flow Margin | -438.64% | -351.07% | -51.03% | -1369.57% | -222.24% | Upgrade
|
| EBITDA | -21.1 | -26.84 | -17.7 | -25.2 | -18.46 | Upgrade
|
| EBITDA Margin | - | -272.20% | -95.63% | - | -212.99% | Upgrade
|
| D&A For EBITDA | 0.73 | 0.71 | 0.59 | 0.64 | 0.63 | Upgrade
|
| EBIT | -21.83 | -27.55 | -18.29 | -25.84 | -19.09 | Upgrade
|
| EBIT Margin | - | -279.41% | -98.81% | - | -220.22% | Upgrade
|
| Revenue as Reported | 11.96 | 16.8 | 19.86 | 2.31 | 9.58 | Upgrade
|
Updated Mar 21, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.